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Background: F-18-fluordeoxyglucose positron emission tomography (FDG-PET) is
widely used for discriminative diagnosis of tau-positive atypical parkinsonian syndromes
(T+APS). This approach now stands to be augmented with more specific tau tracers.
Therefore, we retrospectively analyzed a large clinical routine dataset of FDG-PET images
for evaluation of the strengths and limitations of stand-alone FDG-PET.
Methods: A total of 117 patients (age 68.4 ± 11.1 y) underwent an FDG-PET exam.
Patients were followed clinically for a minimum of one year and their final clinical diagnosis
was recorded. FDG-PET was rated visually (positive/negative) and categorized as high,
moderate or low likelihood of T+APS and other neurodegenerative disorders. We then
calculated positive and negative predictive values (PPV/NPV) of FDG-PET readings for
the different subgroups relative to their final clinical diagnosis.
Results: Suspected diagnoses were confirmed by clinical follow-up (≥1 y) for 62 out
of 117 (53%) patients. PPV was excellent when FDG-PET indicated a high likelihood
of T+APS in combination with low to moderate likelihood of another neurodegenerative
disorder. PPV was distinctly lower when FDG-PET indicated only a moderate likelihood of
T+APS or when there was deemed equal likelihood of other neurodegenerative disorder.
NPV of FDG-PET with a low likelihood for T+APS was high.
Conclusions: FDG-PET has high value in clinical routine evaluation of suspected
T+APS, gaining satisfactory differential diagnosis in two thirds of the patients. One third
of patients would potentially profit from further evaluation by more specific radioligands,
with FDG-PET serving gatekeeper function for the more expensive methods.
Keywords: atypical parkinsonian syndrome, progressive supranuclear palsy, corticobasal degeneration, F-18-
FDG, PET, clinical routine
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INTRODUCTION
Atypical parkinsonism refers to a group of neurodegenerative
syndromes presenting symptoms resembling those of Parkinson’s
disease (PD), but generally with earlier onset, faster progression,
and poor response to dopamine replacement treatments. Chief
among the atypical parkinsonian syndromes are progressive
supranuclear palsy (PSP) and corticobasal syndrome (CBS),
which both represent tauopathies. Whereas PSP predominantly
presents with a predominantly supranuclear vertical gaze palsy
and early postural instability with falls, CBS typically manifests
as markedly asymmetrical parkinsonism in conjunction with
apraxia or cortical sensory disturbance (1). The incidence of
atypical parkinsonism syndromes is low relative to PD (2), but
their more aggressive course calls for improved discriminative
diagnosis methods and disease specific therapies, such as anti-tau
regimens for PSP and CBS.
The past decade has seen extensive investigations of
brain glucose metabolism by F-18-fluorodeoxyglucose positron-
emission-tomography (FDG-PET) in PSP and CBS patients
(3–8), aiming to detect disease-specific patterns of altered
glucose consumption. Significant reductions of FDG uptake were
observed in PSP subjects in the bilateral anterior cingulate gyrus
and the midbrain (6). In CBS subjects, glucose hypometabolism
was found in the central region, the frontal and parietal
association areas, the putamen contralateral to the clinically
affected side and the bilateral thalamus (7).
Until recently, molecular imaging of glucose metabolism was
not considered by diagnostic (9, 10), even though FDG-PET is
often requested to determine the presence of neurodegeneration
in suspected PSP and corticobasal degeneration (CBD) as the
major subgroup of CBS; however recently proposed diagnostic
criteria now include imaging findings by FDG-PET for PSP
(11). The importance of FDG-PET is underlined by the fact
that the correlation between the clinical diagnostic criteria and
a neuropathological confirmation is still insufficient in suspected
PSP and CBD (12, 13).
Most of the mentioned molecular imaging studies were
performed in academic settings with highly characterized patient
populations to evaluate the FDG uptake patterns, sometimes with
machine learning algorithms. Sensitivity, specificity, positive and
negative predictive values for differential diagnosis of different
parkinsonian syndromes were consistently> 80% in a recent test
of an automated image-derived classification procedure (14). In
clinical routine of a nuclear medicine department, the demands
for differential diagnosis of suspected atypical parkinsonism
by FDG-PET is often more complicated, and hindered by
the less extensive clinical information, a broad spectrum of
possible diagnoses, and missing follow-up data. Besides the high
sensitivity for concomitant dementia in parkinsonian syndromes
even in clinical routine, FDG-PET imparts inherently unspecific
information about synaptic dysfunction, which is the common
thread of all neurodegenerative disorders (15). More recent
developments in molecular imaging for discriminative diagnosis
of PD, atypical parkinsonism, and neurodegenerative diseases in
general focus on disease-specific neuroreceptor changes (16) and
neuropathological hallmarks (17, 18).
The advent of tau-PET imaging presents new prospects for
identification of PSP and CBD with the pyridoindole F-18-
AV1451 (19, 20) and arylquinoline F-18-THK5351 (21, 22) and
their derivatives. In nuclear medicine clinical routine it would
be critical to establish suitable diagnostic algorithms guiding the
decision to augment an established and relatively inexpensive
tracer (FDG) with a less conventional and more expensive tau-
PET investigation; the higher cost must be justified by the
additive diagnostic value. Therefore, we made a retrospective
analysis of clinical routine FDG-PET data obtained during a
7-year period for complex cases referred to a tertiary center
with suspected tau-positive atypical parkinsonism. Our objective
was to determine if FDG-PET findings, in the light of follow-
up to a definite diagnosis, can predict cases where additional
tau-PET examination would potentially have resolved the initial
diagnostic uncertainty. By making this identification of patient
groups we aimed to create a basis for future prospective treatment
trials.
MATERIALS AND METHODS
Study Design and Patient Enrollment
All participants were examined at the Departments of Neurology
and Psychiatry, respectively, and Institute for Stroke and
Dementia Research, and were scanned in a clinical routine setting
at the Department of Nuclear Medicine between 2009 and 2015.
After undergoing cognitive testing and partially assessments of
nigrostriatal innervation by DaTSCAN-SPECT, structural MRI
imaging and CSF sampling, patients with a differential diagnosis
of suspected PSP/CBD were referred for FDG-PET examination.
To avoid a selection bias, all patients with suspected PSP/CBD
in the observation period were considered as a primary sample
(n = 151). Inclusion criteria were defined by at least one
year of clinical follow-up (n = 122) and successful FDG-PET
imaging scan (i.e., no early termination by the patient or not
correctable head motion). Exclusion criteria were earlier events
of stroke (n = 3) or current severe affective disorders (n = 2),
which might influence FDG-PET pattern or clinical features. A
final clinical diagnosis was recorded at clinical follow-up, based
on current diagnostic criteria of parkinsonian syndromes and
other neurodegenerative disorders. One hundred and seventeen
patients with suspected PSP/CBD were eligible for the final
analysis.
Clinical Assessments, MRI and CSF
The majority of patients (61%; 71/117) received
neuropsychological testing including cognitive evaluation at the
time of the FDG-PET scan [Mini-Mental-State Examination
(MMSE)]. Years of education were recorded and a neurological
examination was performed. Symptom categories for clinical
classification of PSP and CBS were assessed binarized (as Yes/No)
at the time of the FDG-PET scan. Patients with suspected PSP
were classified for probable or possible PSP according to NINDS-
SPSP criteria (10), as the observation period of this retrospective
analysis took place before publication of newest PSP criteria
(11). Patients with suspected CBD were classified for probable or
possible CBS according to criteria defined by Armstrong et al.
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(9). The Supplementary Material gives an overview on symptom
categories and their necessary composition for the establishment
of a clinical diagnosis.
Structural MRI (n = 96) and CSF samples (n = 97) were
available from >80% of the 117 patients, whereas DaTSCAN was
performed in less than half of the patients (n= 49; 42%).
PET Imaging
FDG PET Acquisition
FDG-PET images were acquired on a GE Discovery 690 PET/CT
scanner or a Siemens ECAT EXACT HR+ PET scanner. All
patients had fasted for at least 6 h, and had a maximum
plasma glucose level of 150 mg/dl at time of scanning. A single
intravenous dose of 140 ± 7 MBq FDG was administered while
the patients rested in a room with dimmed light and low
noise level, where they remained undisturbed for 20min. After
positioning in the scanner, a series of three static emission frames
of 5min each was acquired from 30 to 45min p.i. on the GE
Discovery 690 PET/CT, or from 30 to 60min p.i. on the Siemens
ECAT EXACT HR+ tomograph. A low-dose CT scan or a
transmission scan with external 68Ge-source performed just prior
to the static acquisition was used for attenuation correction. PET
data were reconstructed iteratively (GE Discovery 690 PET/CT)
or with filtered-back-projection (Siemens ECAT EXACT HR+
PET). After correction for movement between frames, the static
scans were averaged.
Visual Analysis of FDG-PET
For visual image interpretation of FDG-PET images, three-
dimensional stereotactic surface projections (3D-SSP) (23)
were generated using the software Neurostat (Department of
Radiology, University of Washington, Seattle, WA, U.S.A.). A
senior expert in Nuclear Medicine visually assessed axial and
sagittal slices and the 3D-SSP images depicted as normalized
tracer uptake and Z-score maps against reference images from a
group of age-matched healthy controls. The reader had access to
clinical information (available in all cases) and, when available,
DaTSCAN and/or structural MRI information. Based on the
anatomic pattern of hypometabolism the FDG-PET images were
first rated for likelihood (high = A/moderate = B/low = C
likelihood) of a neurodegenerative metabolism pattern
typical for PSP or CBD (24). Next, the FDG-PET scan
was rated for likelihood (high = 2/moderate = 1/low = 0)
of a metabolism pattern typical of a neurodegenerative
condition other than PSP or CBD (mainly Alzheimer’s
disease, PD, frontotemporal lobar degeneration, multiple
system atrophy). Based on permutations of the FDG-PET
findings we defined nine possible subgroups (see Table 1 and
Figure 1).
Additionally the reader had to assert positivity or negativity
for PSP/CBD as a binarized read-out. A likelihood for PSP/CBD
exceeding the likelihood for other neurodegenerative diseases
was defined as positive in this regard, whereas equal or lower
likelihoods in the same comparison were defined as negative.
TABLE 1 | Subgroup definition by FDG-PET findings according to the likelihood
for PSP/CBD (A-C) and other neurodegenerative diseases (0-2).
P
P
P
P
P
P
Other
PSP/CBD
High Moderate Low
Low A-0 B-0 C-0
Moderate A-1 B-1 C-1
High A-2 B-2 C-2
Statistical Analysis
Normality of data distribution was assessed by the Kolmogorov-
Smirnov test. The nonparametric χ2 test was used to test for
significantly differing probability of trichotomous likelihood of
disease-typical FDG-PET patterns (high, medium, low) among
subgroups. The diagnostic accuracy was tested by calculating
the sensitivity, specificity and positive/negative predictive value
(PPV/NPV) using the final clinical diagnosis after ≥ 1 year of
follow-up as the truth. We did not perform an a priori sample
size calculation. A significance level of p < 0.05 for rejection of
the null hypothesis was applied in all analyses. All statistical tests
were performed using SPSS (version 23.0, IBM, Chicago, IL).
RESULTS
Demographics
A total of 117 subjects (51% male) were included in the study
(Table 2). Fifty-three patients (34% male) had been referred
with suspected PSP and 64 patients (52% male) with suspected
CBD. 16 patients were referred with both possible differential
diagnoses, and were assigned to one of the two aforementioned
subgroups according to their more likely diagnosis. The mean
age was 68.4 years (SD ± 11.1). The clinical diagnosis was
confirmed by clinical follow-up ≥ 1 year in 31/53 (59%) patients
with suspected PSP and in 31/64 (48%) patients with suspected
CBD. Additional findings from neuropsychological testing and a
summary of presence or absence of single symptom categories are
provided in the Supplemental Results.
FDG-PET Findings
Proportions of Likelihood Subgroups
According to the matrix defined in section Visual Analysis of
FDG-PET we found 32% of all patients fell in the subgroups
of high likelihood for PSP/CBD in conjunction with low
to moderate likelihood for another neurodegenerative
disorder. A high likelihood for PSP/CBD was assigned
when there was a pronounced FDG hypometabolism in
regions characteristic for PSP (prefrontal cortices, anterior
cingulate gyrus, midbrain)/CBD (central region, putamen,
thalamus), as illustrated and described in Figure 1. Another
32% of the patients indicated a moderate likelihood for
PSP/CBD or equal likelihood for other neurodegenerative
disorders, meaning that the hypometabolism pattern was
of only moderate severity in the characteristic regions.
Thirty-six percent had a low likelihood for PSP/CBD
(Table 3).
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FIGURE 1 | Representative FDG-PET images of study subgrous: Three-dimensional stereotactic surface projections (3D-SSP) of normalized FDG uptake from
right/left lateral (R LAT/L LAT), superior (SUP), inferior (INF), anterior (ANT), posterior (POST), right/left medial (R MED/L MED) views and a subcortical (SC) section
image in the axial pain for four out of nine defined subgroups according to their likelihood for PSP/CBD. In PSP subjects, asymmetrical or bilateral hypometabolism
was found predominantly in the prefrontal cortices, the anterior cingulate gyrus, and the midbrain. In CBS, asymmetrical hypometabolism was observed in the central
region, the putamen and thalamus.
TABLE 2 | Demographics and composition of the study collective.
N Final diagnosis
PSP/CBS
Age (y) Gender
(♂, male, ♀, female)
Education (y) MMSE
All 117 62 (53%) 68.4 ± 11.1 51 ♂ 56 ♀ 13.8 ± 3.6 25.5 ± 4.2
PSP 53 31 (59%) 72.3 ± 8.0 27 ♂ 26 ♀ 14.2 ± 3.5 24.8 ± 4.3
Probable 22 15 (68%) 70.7 ± 7.7 11 ♂ 11 ♀ 13.8 ± 2.5 25.1 ± 3.6
Possible 23 14 (61%) 71.9 ± 7.8 12 ♂ 11 ♀ 14.3 ± 4.5 24.2 ± 4.9
Criteria not fulfilled 8 2 (25%) 77.9 ± 7.8 4 ♂ 4 ♀ 15.0 ± 3.6 25.5 ± 5.8
CBS 64 31 (48%) 65.2 ± 12.3 33 ♂ 31 ♀ 13.6 ± 3.7 26.0 ± 4.1
Probable 17 13 (77%) 70.8 ± 7.3 9 ♂ 8 ♀ 13.6 ± 3.3 26.0 ± 5.7
Possible 21 9 (43%) 61.2 ± 14.0 9 ♂ 12 ♀ 12.3 ± 2.2 25.6 ± 4.4
Criteria not fulfilled 26 9 (35%) 64.9 ± 12.5 15 ♂ 11 ♀ 14.6 ± 4.8 26.2 ± 2.0
TABLE 3 | Proportions of subgroups (n = 117) defined by the likelihood for
PSP/CBD and for other neurodegenerative disorders by visual analysis of
FDG-PET.
P
P
P
P
P
P
Other
PSP/CBD
High (%) Moderate (%) Low (%)
Low (%) 26 18 18
Moderate (%) 6 7 11
High (%) 1 6 7
Overall Performance of FDG-PET
Overall performance of binarized FDG-PET (for likelihood
PSP/CBD > other ND) for the prediction of a final clinical
diagnosis of PSP gave 84% sensitivity, 91% specificity, PPV of
93%, and NPV of 80%. Overall performance of binarized FDG-
PET for the prediction of a final clinical diagnosis of suspected
CBD was slightly lower, at 71% sensitivity, 76% specificity, PPV
of 73%, and NPV of 74%.
Influence of Clinical Probability on FDG-PET Findings
The higher clinical probability by diagnostic criteria indicated
tendencies toward greater likelihood of PSP/CBD and lower
likelihood of other neurodegenerative diseases in FDG-PET.
However, statistical testing did not indicate a significance in these
probabilities (PSPCLINIC – PSPFDG:χ
2 = 6.6; p= 0.16/PSPCLINIC
– otherNDFDG: χ
2 = 0.7; p = 0.95/CBSCLINIC – CBDFDG:
χ
2 = 2.4; p= 0.66/CBSCLINIC – otherNDFDG:χ
2 = 6.4; p= 0.17),
and positive as well as negative PET scans were found in each
clinical category (Table 4).
Overall Performance of FDG-PET in Combination
With Clinical Parameter
The combined evaluation of clinical probability and binarized
FDG-PET for the prediction of the clinical outcome gave
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TABLE 4 | FDG-PET likelihoods for PSP/CBD and other ND for all subgroups.
Subjects (n = 117) FDG-PET likelihood PSP/CBD FDG-PET likelihood other ND
Low Moderate High Low Moderate High
Probable PSP 22 5 7 10 13 6 3
Possible PSP 23 9 6 8 15 4 4
PSP criteria not fulfilled 8 5 3 0 5 2 1
Probable CBS 17 4 7 6 9 4 4
Possible CBS 21 8 5 8 17 3 1
CBS criteria not fulfilled 26 11 8 7 13 9 4
discrepant results for suspected PSP and CBD patients. Thus,
the suspected PSP patients meeting criteria for probable disease
criteria had consistently higher values for PPV, NPV, sensitivity
and specificity by FDG-PET when compared to the whole
cohort, whereas the suspected PSP patients with only possible
or incomplete disease criteria had lower values of these
diagnostic accuracy parameters (Figure 2A). Suspected CBD
patients meeting probable disease criteria for CBD had a higher
PPV but lesser NPV and sensitivity (at equal specificity) by FDG-
PET when compared to the whole cohort. Finally, the suspected
CBD patients with only possible or incomplete disease criteria
showed more sensitivity and higher NPV for FDG-PET when
compared to the whole cohort (Figure 2B).
Performance of FDG-PET in Different Likelihood
Subgroups
Proportions of patients with a final clinical diagnosis of PSP/CBD
differed substantially between the subgroups as defined by FDG-
PET (Figure 3). PPV was excellent when FDG-PET indicated
a high likelihood for PSP/CBD in combination with low to
moderate likelihood for another neurodegenerative disorder
(PSP: 95%/CBD: 89%). PPV was distinctly lower when FDG-
PET indicated only a moderate likelihood for PSP/CBD or when
the likelihood for other neurodegenerative disorders was equal
(PSP: 75%/CBD: 41%). FDG-PET had a high NPV for absence
of PSP/CBD to clinical follow-up when the initial visual read
indicated a low likelihood for PSP/CBD (PSP: 84%/CBD: 83%).
Notably, detection of a metabolism pattern indicative of
moderate synaptic dysfunction in brain regions typical for PSP,
but no suspicion of other neurodegenerative disorders had a far
higher congruency with a positive final clinical diagnosis when
compared to the same constellation in patients with suspected
CBD (compare subgroups B-0 in Figures 3A,B).
Binarized analysis of FDG scans revealing a positive pattern
for PSP indicated a distinctly higher PPV in the absence of
any indication of likelihood for another neurodegenerative
disease, when compared to cases with PSP-positive pattern
in combination with coexisting likelihood for another
neurodegenerative disease (92 vs. 50%). This distinction
was less evident for CBD (68 vs. 63%; Figure 4).
Impact of DaTSCAN Results
DaTSCAN (n = 49) indicated a dopamine transporter deficit
in 65%, a borderline result in 22% and a negative result in
FIGURE 2 | Performance of FDG-PET in clinical subgroups: PPV, NPV,
sensitivity and specificity are illustrated for all suspected PSP (A) and CBD (B)
patients and subdivided into possible or incomplete diagnostic criteria (cnf)
and probable clinical criteria.
12% of the examined cases. Sixty-six percent of those patients
with a pathological DaTSCAN were ultimately diagnosed as
PSP/CBS. Of all 28 patients with the final diagnosis PSP/CBS
and an available DaTSCAN, 75% showed a pathological result,
21% a borderline result and 4% a negative result. When available,
a pathological DaTSCAN together with a pathological FDG-
PET (binarized) result for PSP/CBD (n = 21) gave a PPV
of 76%. Only four patients had overall negative results to
the two imaging modalities, which did not support a valid
calculation of a NPV. PPV was higher and the NPV was
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FIGURE 3 | Performance of FDG-PET in imaging based likelihood subgroups: A confirming final diagnosis was frequent when FDG-PET indicated a high likelihood for
PSP (A)/CBS (B) and only a low to moderate likelihood for other neurodegenerative diseases (Groups A-0 and A-1). A final diagnosis of PSP (A)/CBS (B) was rare
when FDG-PET indicated only a low likelihood for a 4R-tauopathy (groups C-0, C-1, and C-2). ND, neurodegenerative disease.
FIGURE 4 | Examples of conflicting FDG-PET findings in two patients with suspected PSP: Representative 3D-SSP for FDG-PET from right/left lateral (R LAT/L LAT),
superior (SUP), inferior (INF), anterior (ANT), posterior (POST), right/left medial (R MED/L MED) and a subcortical (SC) horizontal plane image of SUV for comparison of
typical AD and PSP metabolic patterns. Note that both patients showed a frontal pronounced hypometabolism but as well an AD-like hypometabolism in the posterior
cingulate cortex and in parietal cortices. Clinical follow-up identified one patient as AD and one as PSP.
TABLE 5 | PPV/NPV values of FDG-PET for PSP and CBD for all subjects and
divided whether a DaTSCAN was available.
FDG-PET PPV (%) NPV (%)
All subjects (n = 117) 83 76
DaTSCAN available (n = 49) 74 64
No DaTSCAN available (n = 68) 90 84
lower for FDG-PET of the (n = 68) subjects without an
available DaTSCAN compared to all subjects and those with an
available DaTSCAN (see Table 5) irrespective of the DaTSCAN
result.
DISCUSSION
In this clinical study we evaluate FDG-PET in a large dataset
of patients with suspicion of PSP or CBD. Previous studies
have established the suitability of FDG-PET for the differential
diagnosis of PSP and CBD (6, 25, 26). However, most of
these investigations were performed in investigational academic
settings with a previously selected patient cohort. Studies in
nuclear medicine routine settings remain rare and challenging
because of more patients with less specific clinical findings and
multiple differential diagnoses in the early stage of disease.
Therefore, we investigated all subjects referred for a FDG-
PET with suspected tau-positive parkinsonism over a period
of 7 years. For selected patient cohorts with PSP and/or CBD,
the typical FDG-PET patterns have already been demonstrated
in group-wise comparisons (5, 7). In clinical routine cases,
the confirmation or exclusion of the suspected diagnosis is
based on a single PET scan of an individual patient which
highlights the importance of a high PPV and NPV for the chosen
method.
Our FDG-PET-findings underline the complexity of the
diagnostic proceeding for patients with clinically diagnosed
parkinsonism with only one third of the patients presenting a
high likelihood for PSP/CBD in the visual FDG-PET analysis.
Nonetheless, performance of FDG-PET was excellent in those
two thirds of the patients, who showed either no clear evidence
of a 4R tauopathy pattern (high NPV) or a typical PSP/CBD
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pattern without conflicting hypometabolism suggestive for other
neurodegenerative disorders (high PPV).
However, one third of patients returned inconclusive scans,
which gave only low likelihood for a 4R-tauopathy or coexistent
hypometabolism patterns typical of other neurodegenerative
diseases. Such patients likely benefit from an additional
evaluation by more specific PET tracers. Recently developed tau
ligands still have some issues that need to be solved, mainly
consisting of off-target binding to MAO-B (27). Nonetheless,
first human tau PET studies of PSP and CBD already indicated
promising results by F-18-THK5351 (18) and F-18-AV1451
(T807) (19, 28, 29).Moreover, new generation tau tracers promise
to support a differentiation between 3R and 4R tauopathies. Thus,
it seems likely that future tau radioligands will even provide
stronger molecular imaging derived differential diagnosis of 4R
tauopathies. With regards to cost-effectiveness, the decision to
apply such specific but expensive ligands will need to be weighed
carefully. Results of the current study suggest that FDG-PET
should be performed first in a potential diagnostic algorithm
because most clinical suspected diagnosis can be well-supported
by a specific FDG-PET pattern at high PPV and NPV. Although
unspecific for different protein depositions, FDG-PET offers
an advantage as primary molecular imaging method because
of the potential detection of tau-negative neurodegenerative
disorders through their distinct hypometabolism pattern. This
is highly relevant in cohorts of suspected PSP and CBS
patients, as tau-negative variants of fronto-temporal dementia
and multiple system atrophy are potential differential diagnoses.
Based on our current analysis, FDG-PET can also identify
subjects who need further evaluation with additional molecular
imaging such as tau-PET imaging. The current dataset creates
the basis for future prospective trials evaluating diagnostic
algorithms and the additive value of tau-PET in PSP and
CBD.
FDG-PET performed better in patients with suspected PSP
than for patients with suspected CBD probably due to a
more difficult clinical diagnosis (30, 31) and a FDG-pattern
less distinct from other neurodegenerative diseases (6). In
conclusion, suspected CBD patients with conflicting clinical
findings might even profit from an evaluation by a more specific
biomarker such as tau radioligands prior to FDG-PET. However,
since newest PSP criteria now consider non PSP-RS entities as
well, the situation for PSP could as well get more complex, with
an assumed benefit by imaging techniques (11). Dual PET tracer
studies with randomized sequence will be needed to answer this
question.
Our data indicate that clinical probability should be
considered when interpreting a FDG-PET of PSP or CBD
patients and when planning further evaluation. For PSP
patients with a probable clinical likelihood, the higher overall
performance of the method needs to be considered in
comparison with patients that have only possible or absent
diagnostic criteria. Especially the low NPV of a negative FDG-
PET read out in the subcohort of suspected PSP patients with
possible or absent diagnostic criteria has to be stressed. This
subgroup should benefit from further evaluation, where tracers
with higher sensitivity are demanded.
The situation in suspected CBD patients presented even
more complex: First, CBD patients with a probable clinical
likelihood had a very high PPV by a positive FDG-PET, which
implies that positive scans of such patients lead to a very high
diagnostic confidence. On the other hand, we observed only
a very low NPV by a negative FDG-PET in this subcohort.
Thus, negative FDG-PET results of CBD patients with high
clinical likelihood have only a low meaningfulness and further
evaluation by a more sensitive tracer will definitely improve
the diagnostic accuracy in this subgroup. Furthermore the PPV
of a positive FDG-PET in the subgroup of CBD patients with
possible or absent diagnostic criteria was only moderate and
indicated another potential target group for beneficial further
evaluation.
For the detection of PSP, automatic analysis strategies such
as machine learning algorithms revealed a slightly lower PPV
(91 vs. 93%) but a noticeable higher NPV (92 vs. 80%) than
we observed in our sample (14). This comparison should
be interpreted with caution due to the differing population
characteristics. Nevertheless, the majority of clinical nuclear
medicine departments still use visual inspection of axial slices and
surface projection Z-score maps for FDG-PET of patients vs. in
house norm collectives. Although one third of patients did not
show distinct visual FDG-PET patterns to confirm the diagnosis,
the diagnostic modality helps the nuclear medicine clinician to
decide upon a rational recommendation for further evaluation of
the patient.
Dopamine transporter availability was only performed in
less than half of the patients (n = 49/117). This was probably
related to certainty of clinicians about the present parkinsonism
in most of the analyzed patients. Interestingly, the PPV for
combined pathological DaTSCAN and FDG-PET was lower
than for patients with only a pathological FDG-PET. Moreover,
patients without an available DaTSCAN showed a higher
PPV for detecting PSP/CBD by FDG-PET compared to those
with an available DaTSCAN. This indicates the unfavorable
consequence when clinicians order an additional DaTSCAN
if the clinical presentation is inconclusive, which results in a
lower pretest probability, thus presenting a greater diagnostic
challenge for FDG-PET. Due to the limited number of cases
with an available DaTSCAN, we cannot test if dopamine
transporter SPECT would have facilitated the establishment of a
correct differential diagnosis in cases inconclusive to FDG-PET
alone.
LIMITATIONS
The impact of MRI results on the diagnostic accuracy has
not been investigated in this setting. In the present workup,
patients with clear findings in MRI were normally not
referred for molecular imaging by FDG-PET. Thus, we did
not assume an increasing value of analyzing inhomogeneous
MRI findings which do not reflect the patient cohort initially
referred to MRI. It should be noted that this cohort of
clinical routine imaging in nuclear medicine at a tertiary
center definitely underwent preselection steps before going
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to FDG-PET. Thus, the present investigation potentially
presents more complex patients when compared to PSP
or CBD patients referred to a primary care center. Final
diagnoses were based on clinical follow-up ≥ 1 year without
histopathological validation and thus no gold standard was
available as “true” diagnosis. Furthermore, imaging findings
of FDG-PET certainly contributed to the initial establishment
of a clinical diagnosis, especially in cases that did not fulfill
the diagnosis criteria completely. Therefore, some degree of
circular interference cannot be completely ruled out in such a
clinical dataset, but the verification of all single items within
the retrospective survey strengthened the validity of clinical
diagnoses.
CONCLUSIONS
We investigated clinical routine cases with the differential
diagnosis of PSP/CBD referred for a FDG-PET to reveal the
diagnostic value for the final diagnosis. FDG-PET showed a
high PPV for subjects with a typical PSP/CBD pattern and
a low likelihood for another ND as well as a high NPV
for subjects without a typical PSP/CBD pattern. One third of
patients (CBD > PSP) showed inconclusive scans and might
profit from further evaluation with more specific radioligands
(e.g., tau), where FDG-PET can act as a gatekeeper for such
more expensive methods. This subgroup represents an ideal
cohort for testing the additive value of tau radioligands in
prospective trials for 4R tauopathies. Clinical probability by
diagnostic criteria should be considered together with FDG-PET
findings when evaluating the benefit of scanning with additional
ligands.
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